Keywords
Couple year of protection, post-partum, intrauterine device, contraceptive implant, Rwanda
Couple year of protection, post-partum, intrauterine device, contraceptive implant, Rwanda
In this revision, we clarify that the salaries paid to study coordinators and data managers were in fact for implementation. We are reporting on findings from an implementation study, and during the implementation, coordinators were responsible for arranging training activities, organizing PPIUD certifications, scheduling providers across the hospitals and health centers, and managing other implementation logistics. Data managers were responsible for extracting the government log book data to enable monitoring of PPIUD uptake and occurrence of PPIUD side-effects (e.g., infections) and expulsions. We envision that these would be regular activities required to implement and monitor a large-scale implementation. We have also addressed several minor concerns.
The Introduction has been improved with transition sentences, clarification of the country data source of Pasha et al., 2015, noting the duration of the hormonal IUD, and noting the relatively high proportion of implant use in Rwanda.
In the Discussion, we clarify that while the IUD was promoted in the context of the full range of method options, we dedicated more time to discussing the PPIUD because this method was less well known. We also discuss the importance of PPIUD provision in infant vaccination settings. Projet is spelled correctly (French spelling). Many thanks for the opportunity to further improve this manuscript.
See the authors' detailed response to the review by Aisha N.Z. Dasgupta
Voluntary family planning (FP) is one of the most cost-effective public health interventions, reducing both maternal and child mortality and improving national economies1. Postpartum FP in particular is critical to improve maternal-child health via birth limiting and spacing2. However, there is high unmet need for family planning in the developing world, especially in postpartum periods. In postpartum periods, 61% of women across 21 low- and middle-income countries experienced unmet need3, while 95% of women across 5 countries desired to avoid pregnancy for at least 1 year after delivery4. In Rwanda, although only 2% of postpartum women report a desire for another child within 2 years of delivery, the unmet need in the postpartum period is 51%5.
To meet women’s postpartum fertility goals and improve maternal-child health via birth spacing or limiting6, the Rwandan government has made postpartum family planning a key objective of the Rwandan Family Planning 2020 Commitment (Objective 2: ‘Scale up the postpartum family planning (PPFP) in all health facilities in Rwanda to increase method choice including access to long term methods…’) with the goal of preventing 250,000 unintended pregnancies annually7.
Long-acting reversible contraceptive (LARC) methods (the hormonal and copper intrauterine device (IUD) and hormonal implant) are not only the most effective reversible methods (lasting 5–10 and 3–5 years, respectively, with typical use failure rates <1%/year), but are very cost-effective8–12. A copper postpartum IUD (PPIUD) can be inserted immediately after delivery of the placenta, during a cesarean delivery, up to 48 hours after childbirth, or beginning at 4 weeks after delivery13,14 (https://www.mcsprogram.org/resource/pathway-of-opportunities-for-postpartum-women-to-adopt-family-planning/). A postpartum (PP) implant can be inserted any time after delivery (https://www.mcsprogram.org/resource/pathway-of-opportunities-for-postpartum-women-to-adopt-family-planning/). and the WHO Medical Eligibility Criteria were recently revised for postpartum implants15. IUDs make up a relatively small share of method use in Rwanda (2.5% of the method mix), while implants make up 16.9% of the method mix (http://www.familyplanning2020.org/entities/81).
This relatively low uptake is thought to be related to lack of method promotions to both women and their male partners as well as limited provider comfort counseling on and delivering these methods16–20. Because baseline knowledge about the LARC methods among potential users is lower than for other methods21–25, demand creation strategies must include comprehensive information addressing method benefits, side-effects, and misconceptions21,26,27. To address these issues, funding from a Bill and Melinda Gates Grand Challenge Award was received to improve PPIUD supply and demand in Kigali, Rwanda, with supplementary funding from Emory University to provide PP implant services. Briefly, in two large health centers (providing antenatal care (ANC), family planning, and infant vaccination services), their two adjoining referral hospitals (providing routine and complex labor and delivery), and two additional large health centers (providing ANC, family planning, routine labor and delivery, and infant vaccination services), Emory-based non-governmental organization Projet San Francisco (PSF) developed and implemented PPIUD and PP implant promotional counseling and service delivery procedures in August 2017. The PPIUD and PP implant were promoted during ANC and labor and delivery to target women prior to delivery. Promotions also occurred during infant vaccination visits which have been shown to be an acceptable and high-impact venue to reach postpartum women in Rwanda28 and are considered a potentially high-impact target for integration since immunization services have broad reach29. By July 2018, 9,073 pregnant women received PPIUD/PP implant promotions who later delivered in one of our selected facilities. Of those, 2,633 had PPIUDs inserted, and 955 had PP implants inserted. These published findings represented a significant increase in PPIUD and PP implant uptake versus the 6 months prior to our implementation (p<0.001)30.
The goal of the present analysis is to detail expenditures during the implementation and estimate the incremental cost per PPIUD insertion, PP implant insertion, and couple years of protection (CYP) for PPIUD and PP implant users to inform decision-making by the Ministry of Health and to estimate the cost of scaling up activities. Importantly, in addition to the costs of labor and supplies, the costs of promotional activities are included when calculating the costs and cost-effectiveness estimates of this intervention because postpartum LARCs are still relatively unknown (this is especially true for the IUD for which baseline knowledge is low21–25) and require a significant investment in demand creation.
The PPIUD/PP implant intervention (described in detail previously30) was developed with input from stakeholders, providers, community health workers (CHW), and couples/clients. Stakeholders included the Rwanda Ministry of Health, the District Mayors, the Rwandan Family Planning Technical Working Group, and clinic directors. Through formative work between May and July 2017, we evaluated knowledge, attitudes, and practices regarding PPIUD/PP implant services among community health workers and providers and clients/couples. This formative work led to the development of intervention operational procedures and a promotional counseling flipchart to be delivered to women or couples. Promotional counseling was conducted primarily by counselors during ANC, labor and delivery, and infant vaccination services or within the community by CHW. In addition, dedicated promoters were hired to administer promotions. In August of 2017, nurses and midwives working in labor and delivery and family planning departments began training in PPIUD insertions (implant insertion training had been previously provided). Clinic staff and CHWs were trained to promote the PPIUD/PP implant services. Follow-up appointments were scheduled for PPIUD clients within 6 weeks after PPIUD insertion (typically coinciding with the 6-week infant vaccination visit).
Pre-intervention postpartum LARC services were conducted by two national PPIUD trainers located at two of our selected district hospitals. One of these national PPIUD trainers was collecting PPIUD insertion and follow-up data in a logbook specifically for PPIUD services. In the 6-months prior to our intervention (from February-July 2017), n=46 PPIUDs were inserted (average of 7.7 insertions/month) and n=182 PP implants were inserted (average of 30.0 insertions/month) in the selected health facilities. The percent increase comparing monthly PPIUD insertions between February-July 2017 to our intervention period of August 2017-July 2018 was 2,687% for PPIUD and 169% for PP implant.
We used a standard, comprehensive micro-costing approach as recommended to calculate the incremental cost of the PPIUD/PP implant intervention from the health system perspective31. Using standardized data collection tools, resource use data was collected from expenditure records, study case report forms, and interviews with program implementers. Costs of labor, promotions, and supplies are included as detailed below, and no research costs are included. Thus, the costs included are the incremental costs required to implement the promotional counseling and service delivery intervention above the minimal existing pre-intervention postpartum LARC services described above. Study coordinators and the nurse counselor were responsible for arranging training activities, organizing PPIUD certifications, scheduling providers across the hospitals and health centers, and other implementation logistics. The data manager was responsible for extracting and recording the government logbook data to enable monitoring of PPIUD uptake and occurrence of PPIUD side-effects (e.g., infections) and expulsions. We envision that these would be regular activities required to implement and monitor a large-scale implementation. Part-time salaries and fringe were provided for three Emory staff and the PSF Director. PSF-based personnel included a dedicated physician with part-time support from two project physicians, two study coordinators, a senior nurse counselor, a data manager, and two promotions managers.
Per diems were provided for trainees during training activities. Training costs included the costs of training providers to insert PPIUDs during a 2-day didactic training and mentored practical certification process, and the costs of training PPIUD/PP implant promotional agents. Field travel included travel for Emory-based staff and transportation for local staff. Field travel was required to transport staff to trainings (which would be recurring during future implementation stages) and the implementation clinics. Other field expenses included wire transfer fees, transcription and translation services, and meals during trainings. Transcription and translation services were required to produce implementation tools in two of the main languages spoken in Rwanda (Kinyarwanda and French).
Recruitment/reimbursement expenses began in February/March 2018 and included: PPIUD client transport reimbursement for follow-up visits ($2.29 United States Dollars [USD]/client), reimbursements for CHW promoters ($0.57 USD/client presenting their referral when requesting a PPIUD or PP implant), reimbursements for providers ($1.20 USD/PPIUD and $0.57 USD/PP implant insertion), and reimbursements to the selected facilities for administrative costs associated with implementing the PPIUD/PP implant program ($57 USD/facility/month). CHW and clinic provider reimbursements used the Rwandan performance-based-financing (PBF) system as a guide32. Reimbursements for providers included the cost of providers’ time/labor to provide insertions. This was provided to them in addition to their regular salary (the average monthly salary for family planning or labor and delivery nurses is $124-364 USD, depending on their education). Communications expenses included internet and phone airtime for staff. Field consumables/office supplies included specula, forceps, batteries, logbooks, chargers for tablets, PPIUD kits and various office supplies. Tablets were used to collect data from logbooks for quality assurance/control.
We also included the cost of methods (estimated from the prices incurred by the United Nations Population Fund (UNFPA) in 2015 of $0.37 USD per copper T380 IUD and $8.93 USD per Jadelle levonorgestrel rod implant (http://mshpriceguide.org/en/home/), and converted to 2018 USD ($0.39 and $9.49 USD, respectively). Expenditures are reported by activity in 2018 USD.
Only implementation costs related to service provision were included (i.e., we did not include research costs for formative work conducted between May and July 2017). Thus, the expenses presented represent the frontline incremental costs required to implement the program between August 2017 and July 2018 from the health system perspective. No discounting of costs was performed given the short time horizon. We follow the Consolidated Health Economic Evaluation Reporting Standards31.
Outcomes of interest include the number of PPIUDs and PP implants inserted and the cumulative couple years of protection (CYP) for PPIUD and PP implant users. CYP is a commonly used estimate of the length of contraceptive protection against pregnancy provided per unit of that method and is estimated at 4.6 for the Copper T380 IUD and 3.8 CYP for Jadelle (5 year) implant33 (https://www.usaid.gov/what-we-do/global-health/family-planning/couple-years-protection-cyp). Using the incremental cost measures and outcomes of interest, we calculated the cost per PPIUD inserted, cost per PP implant inserted, cost per CYP for PPIUD users, and cost per CYP for PP implant users. No discounting of outcomes was performed given the short time horizon of the 12-month implementation.
The Emory University Institutional Review Board (IRB) and the Rwanda National Ethics Committee (RNEC) approved the research component of the project (IRB 00001497). Written informed consent was obtained from all participants prior to enrollment. The Emory University IRB determined the programmatic service delivery component of the project (PPIUD promotions and insertions performed in government clinics) was exempt from review.
Raw data for this study are available in Dataset 134.
Program costs are summarized in Table 1. A total of $74,147 USD was spent on the implementation between August 2017 and July 2018. The largest expense (34% of total expenses) went toward personnel, including doctoral-level (MD and PhD) staff, and administrative, data management and nurse counseling staff. Trainings for PPIUD and implant promotional counselors and PPIUD providers comprised 8% of total expenses. Recruitment and reimbursements comprised 6% of expenses. Costs of implants to the government comprised 12% of the expenses, much higher than the cost of IUDs (1%).
Only direct costs included; all costs in 2018 USD.
Costs incurred by implementation team | USD | Percentage of total |
---|---|---|
Salaries and fringe: PSF and clinic staff | $25,051 | 34% |
Salaries and fringe: Emory employees | $14,225 | 19% |
Trainings | $6,099 | 8% |
Field travel | $5,363 | 7% |
Other field expenses | $5,820 | 8% |
Recruitment/reimbursement | $4,510 | 6% |
Communication | $1,427 | 2% |
Field consumables/office supplies | $1,129 | 2% |
Field facilities | $433 | 1% |
Cost of methods | ||
Cost of implants* | $9,063 | 12% |
Cost of IUDs* | $1,027 | 1% |
Total Expenses | $74,147 |
Program outcomes are summarized in Table 2. Costs per insertion were $25/PPIUDs and $77/PP implant. Costs per CYP were $5/PPIUDs and $20/PP implant.
All costs in 2018 USD.
IUD outcomes | Value |
---|---|
PPIUDs inserted (N) | 2,633 |
Cumulative CYP for PPIUD users* | 12,112 |
Cost per PPIUD inserted | $25 |
Cost per CYP for PPIUD users | $5 |
Implant outcomes | |
PP Implants inserted (N) | 955 |
Cumulative CYP for PP implant users* | 3,629 |
Cost per PP implant inserted | $77 |
Cost per CYP for PP implant users | $20 |
Our implementation provided services at a cost per insertion of $25 and $77 for the PPIUD and PP implant, respectively, and CYP of $5 and $20 for the PPIUD and PP implant, respectively. Understanding the cost per PPIUD/PP implant inserted can help to inform decision-making by the Ministry of Health and to estimate the cost of scaling up PPIUD/PP implant service implementation activities. Since cost per CYP is a standard and commonly used measure, our estimates of cost of CYP also help the government to determine contraception funding priorities.
For comparison, in a previous study conducted in Rwanda, 478 PPIUDs were inserted over 15 months in 12 sites at an incremental cost of $95,004 USD. After amortization of training costs over three years, investigators estimated outcomes of $110/PPIUD inserted and $24/CYP for the PPIUD16.
Though few additional postpartum contraception studies exist for comparability, other studies (summarized in Table 3) have made estimates of method cost per CYP, though not specifically in postpartum periods. The World Bank estimated that the cost per CYP for reversible modern methods in Ethiopia, Uganda, Burkina Faso, and Cameroon was lowest for the IUD ($4.14-$23.35), while the costs per CYP for oral contraceptive pills (OCPs) ($17.00-$31.45) and implants and injectables ($19.84-$58.54) were much higher35. Using data from 13 USAID tier one priority reproductive health countries and service delivery costs, researchers estimated that the cost per CYP was $1.37 for the copper IUD, $4.67 for Sino-Implant, $7.07 for DMPA, $6.88 for combined OCPs, and $4.06 for Jadelle36. Finally, a study in Zambia estimated costs per CYP were $8.69 for the IUD and $15.15 for the implant37.
Method | CYP | Reference |
---|---|---|
Copper IUD | $1.37-$23.35 | 35–37 |
Implant | $4.06-$15.15 | 36, 37 |
OCP | $6.88-$31.45 | 35, 36 |
DMPA injectables | $7.07 | 36 |
Implants and injectables (combined in four of the studies included) | $19.84-$58.54 | 35 |
The CYP for the PPIUD and PP implant in our study were within the range of these other non-postpartum focused studies. Although it is difficult to compare estimates of cost per CYP across studies because of different approaches to measuring and including costs and because of the different implementation models used (for example, Neukom et al.37 used a dedicated provider model whereas in our study PPIUD and PP implant services were provided by existing providers in addition to their regular duties with promotions being conducted by those providers and dedicated promoters), these studies indicate that the IUD has the lowest cost per CYP versus other reversible methods, and that estimated costs per CYP are generally higher for the implant versus the IUD, largely because of difference in commodity costs (http://mshpriceguide.org/en/home/).
Importantly, these studies did not include the cost of demand creation activities. The cost of promotional counseling activities is important for implementers to consider when evaluating postpartum and LARC-focused interventions because postpartum LARCs are still relatively unknown and require a significant investment in demand creation. Studies support that such promotional activities should also educate men38–41, as done in this study, which incurs additional costs above focusing promotional activities on women alone. Once social diffusion is achieved and the target population is knowledgeable about postpartum LARC methods, demand creation activities can decrease.
While the IUD was promoted in the context of the full range of method options, we dedicated more time to discussing the PPIUD because it is the least well-known method in sub-Saharan Africa, including in Rwanda22,42–45, which explains the relatively high uptake of the IUD relative to the implant. Other LARC implementation studies have observed that the implant is more popular than the IUD46,47 but that this trend shifts after focused IUD educational and counseling efforts, community-based and media efforts, and provider refresher IUD trainings25,48. Thus, though the IUD is less well-known versus the implant in much of sub-Saharan Africa22,42,43,45,49 and providers may have lower baseline comfort promoting and inserting IUDs18–20, concerted promotional counseling and training efforts can be successfully employed as was achieved in these examples and our study to increase IUD demand.
There is very limited literature on the cost of the PP implant, making our findings timely especially in light of the WHO Medical Eligibility Criteria (MEC) updates related to the postpartum implant15. Women who are <6 weeks postpartum and breastfeeding can use the implant with a MEC of 2 (meaning the method is generally recommended) while all other women can use the implant regardless of breastfeeding with a MEC of 1 (meaning no restrictions on use). Given the preference for the implant observed in some studies46,47, if the commodity costs for implants were reduced this method could become even more affordable for health systems to scale-up.
Similar to the other studies cited here, we included costs from the health system perspective only; however, we recognize that more detailed costing analyses including the societal perspective including women’s time and the value of their time would be informative and may strengthen evidence to increase LARC services (since women are saved time traveling to clinic for OCP refills or 3-monthly injectables). It would have also been informative to estimate the cost per promotional method employed (e.g., promotions occurring during ANC, labor and delivery, infant vaccination, or delivered in the community by CHW), but as many women received multiple promotions from several places and our promotional strategies evolved over time, this was not possible in the present study. Given our short time horizon, we did not amortize our training costs as in another PPIUD/PP implant in Rwanda16, though the education provided during trainings may translate into service provision over several years in the future; amortization would have decreased our estimated costs per insertion and CYP. We did not collect the data needed to divide the costs of consumables such as specula by their number of uses to arrive at per insertion costs. Additional supplies such as alcohol pads and gauze were among government supplies used and were not measured or included in our calculations. It is not certain whether the cost outcomes estimated here would apply directly larger scale-up activities. We hypothesize that economies of scale may be gained, for example when training a larger number of nurses simultaneously, but it remains to be seen whether quality services can be provided for the same (or reduced) CYP at scale. Finally, our results are most generalizable to sub-Saharan African countries.
There is consensus in the international community that greater investment in postpartum family planning, and the IUD in particular, is needed. We have developed a successful, multi-level intervention that increases PPIUD and PP implant uptake that has relatively low costs per insertion and CYP. Future analyses will explore whether the intervention is cost-effective (or potentially cost-saving).
Underlying data are available from Harvard Dataverse. Dataset 1: Replication Data for an interim evaluation of a multi-level intervention to improve postpartum intrauterine device (PPIUD) services in Rwanda (https://doi.org/10.7910/DVN/WLZ7PC)34.
Data are available under a Creative Commons Zero (“CC0”) Public Domain Dedication Waiver.
This work was supported by the Bill & Melinda Gates Foundation [OPP1160661]. Additional support came from the Emory University Research Council Grant [URCGA16872456], Emory Global Field Experience Award, the Emory Center for AIDS Research [P30 AI050409], the National Institutes of Health [NIAID R01 AI51231; NIAID R01 AI64060; NIAID R37 AI51231], Emory AITRP Fogarty [5D43TW001042], and the International AIDS Vaccine Initiative (IAVI) [SOW2166]. The contents of this manuscript are the responsibility of the authors and do not necessarily reflect the views of the funders.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Views | Downloads | |
---|---|---|
Gates Open Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Demography, family planning
References
1. Jacobstein R: Liftoff: The Blossoming of Contraceptive Implant Use in Africa. Global Health: Science and Practice. 2018. Reference SourceCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: Family planning, health economics, long-acting reversible methods, postpartum family planning and immunization integration
Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
No
Are sufficient details of methods and analysis provided to allow replication by others?
No
If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable
Are all the source data underlying the results available to ensure full reproducibility?
Partly
Are the conclusions drawn adequately supported by the results?
Partly
References
1. Moore Z, Pfitzer A, Gubin R, Charurat E, et al.: Missed opportunities for family planning: an analysis of pregnancy risk and contraceptive method use among postpartum women in 21 low- and middle-income countries.Contraception. 2015; 92 (1): 31-9 PubMed Abstract | Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: Family planning, health economics, long-acting reversible methods, postpartum family planning and immunization integration
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | |||
---|---|---|---|
1 | 2 | 3 | |
Version 4 (revision) 28 Feb 20 |
read | ||
Version 3 (revision) 29 Mar 19 |
read | ||
Version 2 (revision) 08 Feb 19 |
read | ||
Version 1 31 Aug 18 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Register with Gates Open Research
Already registered? Sign in
If you are a previous or current Gates grant holder, sign up for information about developments, publishing and publications from Gates Open Research.
We'll keep you updated on any major new updates to Gates Open Research
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)